Loading...
The Women's Health Initiative (WHI) is an NIH-sponsored, multicenter effort to evaluate therapeutic interventions in postmenopausal women. The arm of the trial that randomly assigned 16,608 women to receive either placebo or conjugated estrogens (0.625 mg/day) plus medroxyprogesterone acetate (2.5 mg/day) was halted in 2002 because hormone recipients showed increased risks for breast cancer, stroke, and heart disease (Journal Watch Women's Health Aug 7 2002). Many publications now are in press reporting outcomes of this arm of the study. JWWH will review these studies under the heading "Women's Health Initiative Update," without reiterating the details of the entire trial. The first of many expected reviews is below.
WHI investigators now re…